2020
Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
Goshua G, Liu Y, Meizlish M, Fine R, Amin K, Chang E, Liu Y, McManus D, Petrosan A, Chaar C, Chun H, Defilippo N, Neuberg D, Owusu K, Lee A. Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. Blood 2020, 136: 23-24. PMCID: PMC8330288, DOI: 10.1182/blood-2020-143349.Peer-Reviewed Original ResearchIntermediate-dose anticoagulationAnti-platelet therapyAnticoagulation cohortOverall cohortMultivariable regression modelingRothman IndexDose anticoagulationHospital deathD-dimerPropensity scoreHospitalized patientsMechanical ventilationClinical trialsCOVID-19Prophylactic-dose anticoagulationRisk-stratified algorithmUse of aspirinChronic kidney diseasePropensity-Matched AnalysisEfficacy of aspirinSeverity of illnessAnti-platelet agentsMulti-site cohortImpact of aspirinSmall vessel thrombosis
2014
Using the Rothman Index to Predict Discharge and Readmission Rates in an Inpatient Hematology Unit
Kim R, Yao X, Longley P, Rimar J, Kournioti C, Lee A. Using the Rothman Index to Predict Discharge and Readmission Rates in an Inpatient Hematology Unit. Blood 2014, 124: 1302. DOI: 10.1182/blood.v124.21.1302.1302.Peer-Reviewed Original ResearchRothman IndexHematologic malignanciesReadmission ratesMedical recordsRA ratesYale Cancer CenterHematology-oncology patientsInpatient oncology unitCommon hematologic malignancyNon-Hodgkin lymphomaAcute myeloid leukemiaHealth care providersHealth care costsElectronic medical recordsDischarge dispositionHospitalized patientsMedian ageHematology unitHM patientsNursing assessmentOncology unitCancer CenterMultiple myelomaMyeloid leukemiaIndividual patients